Samuel Kyeremateng

Dr. Samuel Kyeremateng

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
OHOliver Heinzerling
Oliver Heinzerling
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

7 November 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
OHOliver Heinzerling
Oliver Heinzerling
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

1 March 2018 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
MBMareike Bartels
Mareike Bartels
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

1 January 2021 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
Stefanie Regina WalterStefanie Regina Walter
Stefanie Regina Walter
CLChristian Lübbert
Christian Lübbert
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski
Understanding the long-term stability of amorphous solid dispersions (ASDs) is important for their successful approval for market. ASD stability does not only depend on the interplay between the active pharmaceutical ingredient (API) and the polymer in the final formulation but may already be disadvantageously affected by process steps during the production (e.g. selection of inappropriate solvent for spray drying). Residual solvent can affect the API solubility in the polymer, molecular mobility (by influencing the glass-transition temperature) and induce liquid-liquid phase separation. Enhanced mobility in the ASD due to residual solvent can promote recrystallization in ASDs. The removal of residual solvent can be expensive, time-consuming, and usually requires secondary drying procedures to fulfil the regulatory requirements. The aim of this work is to predict the API solubility in polymer-solvent mixtures, solvent influence on the glass transition, and the occurrence of liquid-liquid phase separation of solvent-loaded ASDs using the thermodynamic model PC-SAFT and to experimentally validate these predictions. ASDs containing the APIs ritonavir or naproxen and the polymers poly(vinyl pyrrolidone), poly (vinyl pyrrolidone- co- vinyl acetate), or hydroxypropyl methylcellulose acetate succinate were spray-dried using the solvents acetone, ethanol, and dichloromethane. API solubility, sorption behavior, liquid-liquid phase separation and glass transition in the ternary API/polymer/solvent mixtures were predicted based on the binary phase behavior between API/solvent, API/polymer, and polymer/solvent and successfully validated experimentally using dynamic vapor sorption (DVS), and Raman spectroscopy. Thus, the presented methodology allows for an in-silico selection of appropriate solvent systems for solvent-based ASD preparation based on a limited amount of experimental data for binary systems only.

1 March 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Stefanie Regina WalterStefanie Regina Walter
Stefanie Regina Walter
CLChristian Lübbert
Christian Lübbert
KLKristin Lehmkemper
Kristin Lehmkemper
SKSamuel Kyeremateng
Samuel Kyeremateng
MDMatthias Degenhardt
Matthias Degenhardt
GSGabriele Sadowski
Gabriele Sadowski

12 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSamuel Kyeremateng
Samuel Kyeremateng
KVKristin Voges
Kristin Voges
Stefanie Regina WalterStefanie Regina Walter
Stefanie Regina Walter
ESEkaterina Sobich
Ekaterina Sobich
ULUte Lander
Ute Lander
MDMatthias Degenhardt
Matthias Degenhardt
Several literature publications have described the potential application of active pharmaceutical ingredient (API)–polymer phase diagrams to identify appropriate temperature ranges for processing amorphous solid dispersion (ASD) formulations via the hot-melt extrusion (HME) technique. However, systematic investigations and reliable applications of the phase diagram as a risk assessment tool for HME are non-existent. Accordingly, within AbbVie, an HME risk classification system (HCS) based on API–polymer phase diagrams has been developed as a material-sparing tool for the early risk assessment of especially high melting temperature APIs, which are typically considered unsuitable for HME. The essence of the HCS is to provide an API risk categorization framework for the development of ASDs via the HME process. The proposed classification system is based on the recognition that the manufacture of crystal-free ASD using the HME process fundamentally depends on the ability of the melt temperature to reach the API’s thermodynamic solubility temperature or above. Furthermore, we explored the API–polymer phase diagram as a simple tool for process design space selection pertaining to API or polymer thermal degradation regions and glass transition temperature-related dissolution kinetics limitations. Application of the HCS was demonstrated via HME experiments with two high melting temperature APIs, sulfamerazine and telmisartan, with the polymers Copovidone and Soluplus. Analysis of the resulting ASDs in terms of the residual crystallinity and degradation showed excellent agreement with the preassigned HCS class. Within AbbVie, the HCS concept has been successfully applied to more than 60 different APIs over the last 8 years as a robust validated risk assessment and quality-by-design (QbD) tool for the development of HME ASDs.